NASDAQ:KRYS

Krystal Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy KRYS

*Your capital is at risk

$301.82

+8.61 (+2.94%)

At Close: Jun 03, 2026

Krystal Biotech Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -37.44. In total, the insiders bought 553.96K and sold 188.03K KRYS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-37.44
● Buy	553.96K shares
● Sell	188.03K shares
44% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Feb 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -37.44. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 27, 2026 Buy	Performance Stock Units M-Exempt	Krishnan Krish S President And CEO	CEO / President	26 250 Value: $7.24M
Feb 27, 2026 Sell	Common Stock F-InKind	Krishnan Suma President, R&d	CEO / President	2 605 Value: $718.0K
Feb 27, 2026 Sell	Common Stock F-InKind	Krishnan Suma President, R&d	CEO / President	11 942 Value: $3.29M
Feb 26, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	2 638 Value: $728.9K
Feb 26, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	5 103 Value: $1.40M
Feb 25, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	700 Value: $192.5K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	569 Value: $149.6K
Feb 24, 2026 Buy	Common Stock M-Exempt	Janney Daniel Director	Director	37 895 Value: $93.2K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	2 425 Value: $666.6K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	930 Value: $250.6K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	1 674 Value: $449.7K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	1 891 Value: $505.6K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	4 339 Value: $1.16M
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	1 604 Value: $425.9K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	900 Value: $238.1K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	1 733 Value: $457.7K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	3 557 Value: $942.9K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	8 986 Value: $2.39M
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	11 673 Value: $3.12M
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	62 Value: $16.3K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	6 671 Value: $1.79M
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	3 963 Value: $1.07M
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	370 Value: $99.8K
Feb 24, 2026 Sell	Common Stock S-Sale	Janney Daniel Director	Director	373 Value: $101.1K
Feb 24, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Janney Daniel Director	Director	37 895 Value: $93.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KRYSTAL BIOTECH INC

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive con...

Read Full Profile Here